Alembic Pharma wins USFDA nod for generic Dapagliflozin, secures 180-day exclusivity

Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.

Fischer Medical converts warrants into equity, infuses Rs 10.53 crore

Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure

Red Nucleus acquires Bridge Medical Consulting with advisory support from VERTICES PARTNERS

As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm

Samsung Biologics lands first US manufacturing facility with GSK acquisition

Samsung Biologics will continue supplying products previously manufactured at the site to GSK

Enveric Biosciences bags key US patent for mental health drug

EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes

Experts advocate holistic Semaglutide use as therapy goes off patent in India

They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market

Senores makes bold US push with new federal-focused JV

Company leadership is framing the move as transformational.

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

Cipla strengthens US respiratory portfolio with final FDA nod for generic Nintedanib

ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA

Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year